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committee of the Spanish Group for Hematopoietic Transplant (GETH)CTLA-4 (cytotoxic T-lymphocyte antigen-4) plays a pivotal role in inhibiting T cell activation through
competitive interaction with B7 molecules and interruption of costimulatory signals mediated by CD28.
Polymorphisms on the CTLA-4 gene have been previously associated with autoimmune diseases, predisposi-
tion to leukemic relapse, and with graft-versus-host disease (GVHD) or relapse after allogeneic transplant.
As CTLA-4 is expressed on T-lymphocytes, the aim of this study was to determine whether the donor
CTLA-4 CT60 genotype also influences clinical outcome even after T cell depletion with CD34-positive
selection. We studied 136 patient-donor pairs. Overall survival (OS) was worse for those patients who
received grafts from a donor with the CT60 AA genotype rather than from a donor with the AG or GG
genotype (35.6% vs 49.4%; P 5 .043). This association was confirmed through multivariate analysis, which
identified the donor CT60 genotype as an independent risk factor for OS (P 5 .008; hazard ratio [HR]:
2.24, 95% confidence interval [CI]: 1.23-4.08). The donor CT60 AA genotype was also associated with lower
disease-free survival, this being related to an increased risk of relapse (P5 .001; HR: 3.41, 95% CI: 1.67-6.96)
and a trend toward higher transplant-related mortality. These associations were stronger when considering
only patients in the early stage of disease. Our results suggest that graft-versus-leukemia (GVL) activity after
T cell depletion is conditioned by the donor CTLA-4 genotype.
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Allogeneic hematopoietic stem cell transplantation
(allo-HSCT) is the treatment of choice for many
haematologic malignancies. However, disease relapse
and graft-versus-host disease (GVHD) remain signifi-
cant concerns after allo-HSCT [1].
Donor T-lymphocytes play a critical role in
alloimmune recognition, leading to GVHD but also
contributing to relapse prevention through recogni-
tion and subsequent elimination of minimal residual
disease [2,3]. Although T cell depletion of the graft
is associated with a lower GVHD incidence, this
benefit is impaired by an increased relapse rate [3-5].
The cytotoxic T-lymphocyte antigen 4 (CTLA-4)
is a homologous molecule of CD28 that modulates
T cell activation. CTLA-4 has greater affinity for B7
than does CD28, and its translocation to the cell sur-
face after T cell activation results in a negative signal,
which is responsible for T cell inactivation [6,7].
Table 1. Clinical Characteristics of the Anayzed Cohort
Patient age: Median: 40 years (range: 17-59).
Patient gender: Male: 75 (55.1%); female: 61 (44.9%).
Diagnosis: AML: 63 (46.3%); CML: 24 (17.6%); ALL: 16
(11.8%); NHL: 14 (10.3%); MDS: 9 (6.6%);
MM: 8 (5.9%); SAA: 1 (0.7%); HD: 1 (0.7%).
Disease status: Early stage: 94 (69.1%); advanced disease: 33
(24.3%); missing data: 9 (6.6%).
Donor age: Median: 41 years (range: 15-64).
Gender mismatch: Male recipient and female donor: 29 (21.3%)
Stem cell source: Peripheral blood: 136 (100%)
Conditioning regimen: Cy-TBI: 81 (59.6%); BuCy: 28 (20.6%); BuCy +
thiotepa: 9 (6.6%); Cy-TBI-Etoposide:
5 (3.7%); other: 13 (9.5%)
CD34 selection: Yes: 136 (100%)
GVHD prophylaxis: CSA alone: 81 (59.5%); CSA + MTX: 17 (12.5%);
CSA + PDR: 30 (22.1%); other: 8 (5.9%).
AML indicates acute myelogenous leukemia; CML, chronic myeloid
leukemia; ALL, acute lymphoblastic leukemia; NHL, non-Hodgkin
lymphoma; MDS, myelodisplastic syndrome; MM, multiple myeloma;
SAA, severe aplastic anemia; HD, Hodgkin’s disease; Cy-TBI, cyclophos-
phamide + total body irradiation; BuCy, busulphan-cyclophosphamide;
CSA, cyclosporine A; MTX, methotrexate; PDR, prednisone.
Advanced disease was considered for patients with acute leukemia
beyond the first complete remission, CML beyond the first chronic
phase, and progressive disease for patients with MDS, MM, or lym-
phoma.
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Several single nucleotide polymorphisms (SNPs) have
been described within the CTLA-4 gene [8]. One of
these SNPs, CT60, is located in the 30-untranslated
region of the gene. Clinically, the CT60 G allele has
been reported to increase susceptibility to several auto-
immune diseases [8-11], and it has also been related
with less leukemic relapse after obtaining complete
remission with standard chemotherapy [12], suggest-
ing that the CT60 AG/GG genotype is associated
with an increased immunologic response. By contrast,
the same genotype has been associated with a lower in-
cidence of GVHD after allogeneic transplantation
[13]. It has been described that the G allele of CT60
produces less soluble isoform of CTLA-4 (sCTLA4)
mRNA than does the A allele, and it has also been hy-
pothesized that sCTLA-4 blocks the B7-full-length
CTLA-4 interaction, thereby enhancing T cell reactiv-
ity by preventing the transduction of inhibitory signals
that lead to lymphocyte inactivation expression [9].
All these studies are focused on the ability of
T-lymphocytes to maintain an autoimmune or alloim-
mune response after antigen recognition. However,
there are no studies regarding the effect of CTLA-4
polymorphisms on alloimmune recognition when
the allo-HSCT is performed with exhaustive T cell de-
pletion through CD34-positive selection (allo-
HSCT-CD34). As CTLA-4 is expressed on the donor
T-lymphocytes, it is not known whether the CTLA-4
genotype may still be important in terms of modulat-
ing of the immune responses that will depend on the
newly generated T cells from the infused stem cells.
The present study aims to determine whether the
CT60 genotype of the donor influences the clinical
outcome of patients receiving an allo-HSCT-CD34
from an HLA-identical sibling donor.PATIENTS AND METHODS
Patients
We analyzed 136 patients who received an alloge-
neic stem cell transplant from an HLA-identical
sibling in Spanish transplant centers between 1996
and 2007. Peripheral blood was the source of stem
cells, and the graft was T cell depleted by positive
selection of CD34 cells in all cases. Patients were all
older than 15 years, and the conditioning regimen
was always myeloablative. Written informed consent
was obtained from patients and donors before DNA
storage. Table 1 summarizes the clinical characteris-
tics of the patients included in this study.CTLA-4 CT60 Genotyping
DNA samples were obtained from donor’s peri-
pheral blood using the QIAamp DNA Blood MiniKit (Qiagen, GmbH, Hilden, Germany), according
to the manufacturer’s instructions and stored at
280C until use. Genotyping of the CTLA-4 CT60
polymorphism was performed by polymerase chain
reaction-restriction fragment length polymorphism
(PCR-RFLP) as previously described [13].Statistical Analysis
The analysis was performed according to the
presence or absence of the G allele on the CT60
polymorphism, with 2 groups being created: patients
receiving a graft from a donor with the CT60 AA
genotype were compared with those whose donor
was homozygous for the G allele or heterozygous
A/G. Homogeneity between groups was assessed by
means of the chi-square test for categoric variables
and the t test for continuous variables. A 2-sided
P value of .05 or lower was considered statistically sig-
nificant. Kaplan-Meier curves were derived to deter-
mine overall survival (OS) and disease-free survival
(DFS), and curves were compared by means of the
log-rank test. Cumulative incidence estimates were
used to explore differences in acute GVHD
(aGVHD), transplant-related mortality (TRM) and
relapse incidence. Death without signs of GVHD
was considered as a competitive risk for aGVHD.
The competing risk for relapse was death in complete
remission (CR).
Multivariate analysis was performed using the Cox
regression model. All the variables with a P value at or
below .2 in the univariate analysis were included in the
multivariate analysis.
Table 2. Homogeneity of the Study Groups
Genotype CT60 AG/GG CT60 AA P value
No. of patients 106 (77.9%) 30 (22.1%)
Median age 39.5 44.7 .019
Gender
Male 56 (52.8%) 19 (63.3%)
Female 50 (47.2%) 11 (36.7%) .307
Diagnosis
Acute leukemia/MDS 70 (66.7%) 17 (56.7%)
Other 35 (33.3%) 13 (43.3%) .313
Disease stage
Early 71 (71.7%) 23 (82.1%)
Advanced 28 (28.3%) 5 (17.9%) .267
Gender mismatch 21 (19.8%) 8 (26.7%) .418
Sensitized donor 18 (22.0%) 10 (40.0%) .072
Conditioning regimen with TBI 69 (66.3%) 21 (70.0%) .707
Prophylaxis
CSA 62 (58.5%) 18 (60%)
CSA + MTX 11 (10.4%) 6 (20%)
CSA + corticosteroids 25 (23.5%) 5 (16.7%)
Other 2 (1.9%) 0 (0%)
Missing data 6 (5.7%) 1 (3.3%) .598
Donor CMV+ 74 (77.9%) 23 (88.5%) .231
Patient CMV+ 74 (75.5%) 24 (85.7%) .252
MDS indicates myelodisplastic syndrome; TBI, total body irradiation;
CSA, cyclosporine A; MTX, methotrexate; CMV, cytomegalovirus.
Comparison between the patiens whose donor had a CTLA-4 CT60
AG/GG genotype and those transplanted from a donor with CT60
AA genotype. Gender mismatch was considered when the donor was
female and the recipient male. Sensitized donors correspond to donors
with previous pregnancies or transfusions. Patient/donor CMV+ indi-
cates positive IgG cytomegalovirus serology.
Figure 1. Overall survival rate after allo-HSCT-CD34 and its relation-
ship to CT60 genotypes. Association between the CT60 genotype and
OS in the whole cohort (A) and in patients transplanted in the early
stage (B).
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CT60 Genotyping
Genotyping showed that 106 donors were CT60
AG/GG and 30 were CT60 AA. The distribution of
genotypes was similar to that previously described in
Caucasian populations [13]. Table 2 shows the com-
parison between these 2 groups. The groups were
comparable when considering the clinical characteris-
tics, the only exception being that patients with the
AA genotype had a higher median age (39.5 vs 44.7
years, P 5 .019).OS
The OS rate at 12 years was better for those
patients who received cells from a donor with the
CT60 AG/GG genotype (49.4%) rather than from
a CT60 AA donor (35.6%), the difference being statis-
tically significant (P 5 .043) (Figure 1A). Median
survival was 6.1 years for patients receiving grafts
from CT60 AG/GG donors and 1 year for patients
transplanted from CT60 AA donors.
This difference in OS according to donor geno-
type became more evident when analyzing only pa-
tients transplanted in the early stage of the underlying
hematologic malignancy (defined as first CR [CR1] for
acute leukemia, first chronic phase [CP1] for chronic
myeloid leukemia (CML), or at least stable diseasefor the rest of the hematologic malignancies): 63.1%
versus 33.2%, P 5 .003 (Figure 1B).
We analyzed a more homogeneous group defined
by the diagnosis, looking at the OS for patients
with acute myelogenous leukemia (AML), acute
lymphoblastic leukemia (ALL), and myelodysplastic
syndromes (MDS), which represent currently the
main indications for allogeneic transplantation. We
found that OS was still better for those patients
transplanted from a donor with the CT60 AG/GG
genotype (n 5 70) compared with those whose donor
was homozygous for the A allele (n 5 17): 49.4%
versus 26.5% reaching a trend to the statistical
significance (P 5 .068), which was confirmed when
considering only patients transplanted in early stage
(68.3% vs 26.9%; P 5 .009).
Multivariate analysis confirmed that the donor
CT60 genotype was an independent risk factor for
overall survival (P 5 .008; HR 5 2.24, 95% CI 5
1.23-4.08), together with advanced disease stage at
transplant (P 5 .001; HR 5 2.63, 95% CI 5 1.50-
4.62) and the use of total body irradiation (TBI) as
Table 3. Multivariate Analysis and Clinical allo-HSCT-CD34
Outcome
Variables P value HR (95% CI)
Overall survival
Donor CT60 AA genotype .008 2.24 (1.23-4.08)
Advanced disease .001 2.63 (1.50-4.62)
Total body irradiation .035 1.84 (1.04-3.25)
Gender .330 —
Diagnosis .189 —
Age of patient .320 —
Sensitized donor .528 —
Disease-free survival
Donor CT60 AA genotype <.001 2.94 (1.67-5.18)
Advanced disease <.001 3.34 (1.92-5.80)
Age of donor .279 —
Prophylaxis .665 —
Sensitized donor .061 —
Relapse incidence
Donor CT60 AA genotype .001 3.41 (1.67-6.96)
Disease stage <.001 4.88 (2.45-9.71)
Age of donor .240 —
Prophylaxis .395 —
Sensitized donor .126 —
HR indicates hazard ratio; CI, confidence interval; HSCT, hematopoietic
stem cell transplantation.
Figure 2. Disease-free survival rate after allo-HSCT-CD34 and its
relationship to CT60 genotypes. Association between the CT60
genotype and DFS in the whole cohort (A) and in patients transplanted
in the early stage (B).
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95% CI 5 1.04-3.25) (Table 3).
DFS
The DFS rate was also influenced by the donor
CTLA-4 CT60 genotype: patients receiving grafts
from a donor with the CT60 AG/GG genotype had
better DFS than did those whose donor was CT60
AA (41.3% vs 13%, P5 .011) (Figure 2A). This differ-
ence in DFS was also detected when analyzing only pa-
tients in the early stage of the underlying hematologic
malignancy (51.2% vs 12.4%, P 5 .002) (Figure 2B).
When analyzing only patients with acute leukemia
or MDS, DFS was also better for patients transplanted
from donors with the AG/GGCT60 genotype (45.1%
vs 14.1%; P5 .052), especially when considering only
patients transplanted in an early stage of their disease
(59.8% vs 14.4%; P 5 .016).
The association between the donor CT60 AA ge-
notype and worse DFS was confirmed by multivariate
analysis (P\ .001; HR 5 2.94, 95% CI 5 1.67-5.18),
which also revealed the disease stage as a relevant risk
factor (P \ 0.001; HR 5 3.34, 95% CI: 1.92-5.80)
(Table 3).Relapse Incidence
The univariate analysis considering competitive
risks found no statistically significant difference in
the relapse incidence between patients according to
whether grafts were received from a donor with the
CT60 AG/GG or AA genotypes (42.3% vs 57%,
respectively, P 5 .320). However, when considering
only patients transplanted in the early stage of their
disease, a trend toward a statistically significant higherrelapse incidence was observed for patients whose
donor was genotyped as CT60 AA (31.8% for geno-
types AG/GG vs 57.1% when the donor was
homozygous for the A allele, P 5 .052). Multivariate
analysis identified the CTLA-4 CT60 genotype of
the donor as an independent risk factor for relapse
(P5 .001; HR5 3.41, 95% CI5 1.67-6.96), together
with the disease stage at transplant (P\ .001; HR 5
4.88, 95% CI 5 2.45-9.71) (Table 3).
We did not observe any effect of the CTLA-4
CT60 G allelic dose neither in OS nor in DFS, obtain-
ing similar results for those patients transplanted from
a donor with CT60 genotype AG or GG.TRM
There was also a trend toward statistical sig-
nificance when considering the differences in
TRM between patients according to whether the
donor was CT60 AG/GG or CT60 AA (17.4% vs
30%; P 5 .104). However, the multivariate analysis
104 Biol Blood Marrow Transplant 18:100-105, 2012A. Bosch-Vizcaya et al.failed to obtain statistically significant differences
(P 5 .146).
GVHD
No differences were detected regarding the inci-
dence of either grades II-IV aGVHD (21.8% vs
20%, P 5 NS) or grades III-IV aGVHD (8.2% vs
6.6%, P 5 NS). The incidence of extensive chronic
GVHD (cGVHD) was also similar in the 2 groups
(11.6% vs 12.5%, P 5 NS).DISCUSSION
We have previously described how CTLA-4 gene
polymorphisms are involved in the immune response
following allo-HSCT from an HLA-identical sibling
donor, as well as in the immune surveillance that
leads to a lower relapse incidence after obtaining com-
plete remission in acute leukemia [12,13]. However,
there are no clinical observations concerning the
role of CTLA-4 after allo-HSCT-CD34. As donor
T-lymphocytes are removed from the graft, immuno-
logic responses, including recognition of the minimal
residual disease, have to be mediated by the newly gen-
erated T cells from the graft. This T cell repopulation is
usually delayed after positive CD34 selection [14], and
one question to be answered is whether the CTLA-4
genotype of these newly generated T-lymphocytes
remains relevant for the clinical outcome.
The present study has identified the CTLA-4
CT60 AA genotype of the donor as an independent
risk factor for worse OS after allo-HSCT-CD34.
This finding is associated with an increased risk of
relapse, suggesting that CTLA-4 also plays an impor-
tant role in modulating the recognition of minimal
residual disease, even when T-lymphocytes are gener-
ated from the infused CD34 cells. In other words,
T cell depletion impairs the graft-versus-leukemia
(GVL) effect, as previously reported, but the CTLA-4
genotype of the donor appears to distinguish 2 cohorts
of patients: those whose donor had the CT60 AG/GG
genotype would benefit from a certain GVL effect,
whereas those whose donor was CT60 AA would
not. However, we must consider that most of our
patients received cyclosporine, which dampens T cell
function, and perhaps our observations may not apply
to CD34 selection strategies where no additional
GVHD prophylaxis is given.
Interestingly, the donor CT60 genotype produced
no differences in either the aGVHD or cGVHD inci-
dence in our patients. In the case of aGVHD, this is
probably because of the almost complete absence of do-
nor T-lymphocytes during the first months after
infusion. A more relevant finding is the association of
CT60AG/GGwith a lower relapse incidence butwith-
out developing more cGVHD, suggesting a separation
between theGVHD andGVL effects in these patients.It is worth noting that the observed association
between the donor CTLA-4 CT60 AG/GG genotype
and both lower relapse incidence and better survival is
consistent with previous studies that show a higher
incidence of autoimmune diseases in people carrying
this genotype [9], as well as with the lower relapse
rate observed for acute leukemia patients with the
CT60 AG/GG genotype after achieving complete
remission with standard induction chemotherapy [12].
Taken together, these observations suggest a lower
CTLA-4 inhibitory response of T cell activation, lead-
ing to enhanced immune surveillance in the presence
of at least 1 CT60 G allele. Surprisingly, this CT60
genotype has been related not only with less aGVHD
but also with a higher relapse rate and worse survival
after allo-HSCT from an HLA-identical sibling per-
formed with a myeloablative conditioning regimen
and without T cell depletion [13]. The hypothesized
mechanism underlying this differential behavior in
the allogeneic setting was that the lower production
of the CTLA-4 soluble isoform observed in the
presence of the CT60 AG/GG genotype could be
important in modulating the immune response to allo-
geneic peptides, such as minor histocompatibility anti-
gens. However, the present results provide new data
concerning the role of CTLA-4 after allogeneic
transplantation, suggesting that the T-lymphocyte
response is different when these cells are infused
together with the graft, as opposed to being newly gen-
erated from the pluripotent stem cell. One possible
explanation for this observation could be that the
T-lymphocyte repopulation after allogeneic stem cell
transplantation with positive selection of CD34 cells
is often delayed beyond 3 months after transplantation
[14], when the tissue-associated antigen-presenting
cells (APCs) have already been replaced and become
of donor origin [15,16]. As a consequence of this
change, these APCs would not present peptides
proceeding from endogenous proteins of the
recipient, such as minor histocompatibility antigens,
thereby leading to an immunologic scenario similar to
the autologous setting.
We conclude that the CTLA-4 genotype influ-
ences immunological responses after allo-SCT from
HLA-identical sibling donors, even after exhaustive
T cell depletion.ACKNOWLEDGMENTS
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